New pill plus immunotherapy shows promise for liver cancer
NCT ID NCT06680258
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 3 trial tests whether adding an experimental drug (TPST-1120) to standard immunotherapy and anti-angiogenic therapy helps people with advanced liver cancer live longer. About 740 adults whose cancer cannot be surgically removed or has spread will be randomly assigned to receive either the new combo or a placebo plus standard care. The study will also check safety and tumor shrinkage.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TPST-1120 (a drug taken by mouth) combined with atezolizumab and bevacizumab (both given by IV)
What this could lead to
If successful, this combination could become a new standard treatment for advanced liver cancer, helping patients live longer and slowing cancer growth.
What could go wrong
This is a phase 3 trial, but it's still experimental. The added drug may not improve outcomes over current therapy, and side effects could be more severe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••